ESR1 and breast carcinoma: A new study combining the pure anti-estrogen fulvestrant with BZ suggested that the combination of anti-estrogen therapies with proteasome inhibition might increase treatment efficacy in estrogen receptor α-positive-breast cancer cell lines (18).